Personalized Cancer Vaccine Given After Adjuvant Therapy Safe, Shows Early Efficacy in Multiple Tumor Types
Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and showed potential clinical benefit in patients with diverse tumor types with high risk of recurrence, according to results from a phase I clinical trial presented during Week 1 of the virtual AACR Annual Meeting 2021, held April 10-15.